Sandoz teams up with World Child Cancer to “even the odds” for children worldwide

Holzkirchen, February 15, 2016 – Sandoz, together with leading global charity World Child Cancer (WCC), is pleased to announce a new health initiative in the Philippines, aimed at improving the standard of care for children suffering from cancer.

Cancer survival rates for children in the Philippines are less than 20%, compared to an average of 80% in developed countries. The goal of the new partnership, further details of which will be announced next month, is to help “even the odds” by supporting the development of specialist treatment centers in the island region …

/by

Sandoz advances its biosimilars program with EMA acceptance of regulatory submission for biosimilar pegfilgrastim

  • Sandoz’ late-stage biosimilar pipeline gains momentum with sustained investment – five of 10 planned regulatory filings achieved

  • Sandoz believes that the totality of evidence in its submission, including three pivotal clinical studies, demonstrates that the proposed biosimilar is highly similar to the reference product.

  • Sandoz is the European market leader in both the daily G-CSF class and for biosimilar filgrastim.

Holzkirchen, 11 February, 2016 – Sandoz, a Novartis company and the global leader in biosimilars, …

/by

Sandoz advances its biosimilars program with EMA acceptance of regulatory submission for biosimilar pegfilgrastim

  • Sandoz’ late-stage biosimilar pipeline gains momentum with sustained investment – five of 10 planned regulatory filings achieved

  • Sandoz believes that the totality of evidence in its submission, including three pivotal clinical studies, demonstrates that the proposed biosimilar is highly similar to the reference product.

  • Sandoz is the European market leader in both the daily G-CSF class and for biosimilar filgrastim.

Holzkirchen, 11 February, 2016 – Sandoz, a Novartis company and the global leader in biosimilars, …

/by

Sandoz’s Carol Lynch elected as chair of EGA’s European biosimilars group

Holzkirchen, February 10, 2016 – Today, Sandoz announced that the European Generic Medicines Association (EGA) has elected Carol Lynch, Global Head Biopharmaceuticals & Oncology Injectables, Sandoz as Chair of its European Biosimilars Group (EBG).

In this role Lynch, along with fellow EBG members, will support the expansion of patient access to high-quality biosimilar medicines, while ensuring the sustainability of the industry. Lynch believes that the industry’s areas of focus, under her tenure, for the next two years should be: 

  • Increasing …
/by

Sandoz’s Carol Lynch elected as chair of EGA’s European biosimilars group

Holzkirchen, February 10, 2016 – Today, Sandoz announced that the European Generic Medicines Association (EGA) has elected Carol Lynch, Global Head Biopharmaceuticals & Oncology Injectables, Sandoz as Chair of its European Biosimilars Group (EBG).

In this role Lynch, along with fellow EBG members, will support the expansion of patient access to high-quality biosimilar medicines, while ensuring the sustainability of the industry. Lynch believes that the industry’s areas of focus, under her tenure, for the next two years should be: 

  • Increasing …
/by

Novartis delivered strong sales growth and core margin expansion in 2015; announces plans to accelerate growth at Alcon, streamline Group operations

Basel, January 27, 2016 – Novartis delivered strong sales growth and core margin expansion (cc[1]) in 2015; announces plans to accelerate growth at Alcon, streamline Group operations

  • Strong growth (cc) in full year sales, core operating income and core EPS[2]
    • Net sales up 5% (cc) and core operating income up 10% (cc)
    • Core operating income margin up 1.3 percentage points (cc)
    • Operating income (-2% cc) down mainly due to amortization of the new oncology assets
    • Net income (-18% cc) impacted by exceptional gains in …
/by

Novartis delivered strong sales growth and core margin expansion in 2015; announces plans to accelerate growth at Alcon, streamline Group operations

Basel, January 27, 2016 – Novartis delivered strong sales growth and core margin expansion (cc[1]) in 2015; announces plans to accelerate growth at Alcon, streamline Group operations

  • Strong growth (cc) in full year sales, core operating income and core EPS[2]
    • Net sales up 5% (cc) and core operating income up 10% (cc)
    • Core operating income margin up 1.3 percentage points (cc)
    • Operating income (-2% cc) down mainly due to amortization of the new oncology assets
    • Net income (-18% cc) impacted by exceptional gains in …
/by

Sandoz licenses its biosimilar rituximab to Kyowa Hakko Kirin in Japan

Holzkirchen, 25 January, 2016 – Sandoz, a Novartis company and the global leader in biosimilars, announced today that it has entered into an exclusive license agreement with Kyowa Hakko Kirin Co., Ltd for the distribution and promotion of its biosimilar rituximab – a monoclonal antibody, in Japan.

Under the terms of the agreement, Sandoz will file for marketing authorization of biosimilar rituximab and its manufacture if approved. Kyowa Hakko Kirin will be responsible for all sales, marketing and promotion activities in Japan.

Kyowa Hakko Kirin will pay Sandoz …

/by

Novartis moves to address superbug threat

Rex Clements, Head of Business Unit Anti-Infectives & API comments on the antimicrobial resistance declaration:

Listen to the audio (1:23 min).mp3

…

/by

Sandoz advances its biosimilars program with European Medicines Agency (EMA) acceptance of regulatory submission for biosimilar etanercept

  • Sandoz is seeking approval for all indications included in the reference product’s label which includes chronic inflammatory conditions like rheumatoid arthritis and psoriasis.
  • Sandoz believes that the totality of evidence in its submission, including two pivotal clinical studies, will demonstrate that the biosimilar etanercept is highly similar to the reference product.
  • EMA acceptance follows recent FDA regulatory submission acceptance and is the third of ten regulatory filings planned over a three year period (2015-2017).

Holzkirchen, 8 December, …

/by